8-K: Elicio Therapeutics Raises $4.89 Million Through At-the-Market Equity Offering

Elicio Therapeutics has generated approximately $4.89 million in net proceeds by selling 584,170 shares of its common stock through its at-the-market equity offering program since the end of the third quarter of 2023.

Summary

• Elicio Therapeutics has been utilizing an at-the-market equity offering program to sell shares of its common stock.
• The company entered into an agreement on May 16, 2022, allowing them to sell up to $21.0 million worth of shares through sales agents.
• Since the end of the quarter ending September 30, 2023, Elicio has sold 584,170 shares.
• These sales have resulted in net proceeds of approximately $4.89 million for the company, after deducting sales commissions.

Sentiment

Score: 6

Explanation: The document reports a routine capital raise through an established program, which is neither particularly positive nor negative. It's a necessary step for the company's operations.

Positives

• The company successfully raised $4.89 million in capital through its at-the-market equity offering program.
• The at-the-market program provides flexibility in raising capital.

Risks

• The company's reliance on at-the-market offerings could dilute existing shareholders.
• The company may need to raise additional capital in the future, potentially through further share issuances.

Future Outlook

The company may continue to utilize the at-the-market equity offering program to raise additional capital.

Management Comments

• Robert Connelly, President and Chief Executive Officer, signed the report on behalf of the company.

Industry Context

At-the-market offerings are a common method for biotech companies to raise capital, especially when they are in the development stage and need funding for research and clinical trials.

Comparison to Industry Standards

• Many biotech companies, such as Xencor and BioNTech, use at-the-market offerings to raise capital.
• The amount raised by Elicio is relatively small compared to some larger biotech companies, but is typical for a company of its size and stage of development.
• The use of Stifel and Virtu as sales agents is also common practice in the industry.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The company's ability to fund its operations is improved by the capital raise.

Next Steps

• The company may continue to sell shares under the at-the-market equity offering program.
• The company will likely use the raised capital to fund its operations and research.

Key Dates

Keywords

at-the-market offering, equity offering, capital raise, common stock, share issuance, Elicio Therapeutics